Syndax Pharmaceuticals Inc
corporate_fare Company Profile
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for SNDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-04, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for SNDX spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Syndax Q2 Revenue Surges 92% to $72.8M, Loss Narrows; Pipeline Expands with Two New Assets
- Syndax Q2 Revenue Jumps 92% to $73M, Loss Narrows; Pipeline Catalysts Loom
- Syndax Adds Two Pipeline Assets and Lays Out a Catalyst-Rich Roadmap
- Syndax's Revumenib Achieves 82% ORR, 97% CRc in AML Clinical Trials
- Syndax Pharmaceuticals Closes $250M Convertible Senior Notes Offering
Short Interest & Short Volume
14.73 days to coverFINRA reported short interest of 20,660,449 shares in SNDX as of the September 15, 2026 settlement, a 4.7% decrease from the prior period — about 14.7 days to cover at its recent average daily volume. On October 2, 2026, 51.7% of SNDX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SNDX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-10.
$250 Million Convertible Notes Issued · $243 Million Net Proceeds
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →